Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 4/20 | 0.42 |
| ▸ | PPARA | Q07869 | 3/20 | 0.39 |
| ▸ | FFAR4 | Q5NUL3 | 9/20 | 0.39 |
| ▸ | FFAR1 | O14842 | 8/20 | 0.39 |
| ▸ | ALKBH1 | Q13686 | 1/20 | 0.37 |
| ▸ | PTGER4 | P35408 | 2/20 | 0.37 |
| ▸ | PPARG | P37231 | 1/20 | 0.37 |
| ▸ | BCL2 | P10415 | 1/20 | 0.36 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7736088 | 0.91 | PTGER4 (0.44) | GRM2PPARAFFAR4FFAR1ALKBH1 | |
| SCHEMBL7735838 | 0.81 | RORA (0.38) | GRM2 | |
| SCHEMBL7726016 | 0.81 | EDNRA (0.42) | GRM2PPARGMCL1 | |
| SCHEMBL7735544 | 0.80 | EDNRA (0.41) | GRM2FFAR1PPARGMCL1 | |
| SCHEMBL7735825 | 0.78 | GFER (0.48) | GRM2 | |
| SCHEMBL7735771 | 0.75 | GRM2 (0.37) | GRM2 | |
| SCHEMBL7725868 | 0.74 | LPAR1 (0.43) | GRM2 | |
| SCHEMBL7737859 | 0.74 | MEN1 (0.45) | GRM2PPARA | |
| SCHEMBL7725865 | 0.73 | MAPT (0.44) | GRM2 | |
| SCHEMBL7726010 | 0.72 | TOP1 (0.41) | FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6452008-B2 | 3-UREA COMPOUND FROM THE 3-AMIDO COMPOUND WITHOUT AZIDATION PROCESS WHICH HAS RISK OF EXPLOSION; REACTION WITH HYPOCHLORITE, HYPOBROMITE OR LEAD TETRAACETATE AND THEN AN AMINE; ACAT INHIBITOR | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2002-09-17 | — | — | US | disclosed |
| US-20010051732-A1 | Pyridone derivatives and process for preparing the same | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED | 2001-12-13 | — | — | US | disclosed |
| US-6300500-B1 | Preparation of pyridone derivatives using phthalimido containing starting material | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2001-10-09 | — | — | US | disclosed |
| EP-1086948-A1 | PYRIDONE DERIVATIVES AND PROCESS FOR PRODUCING THE SAME | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2001-03-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010051732-A1 | Pyridone derivatives and process for preparing the same | HK1, HPD, ALK | GRM2 3251/4885PPARA 1995/4885FFAR4 2597/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.